Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Fasenra® (benralizumab) – New indication
September 18, 2024 - AstraZeneca announced the FDA approval of Fasenra (benralizumab), for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
